// App-Quantinova.ai

819 : High response rates with entospletinib in patients with t(v;11q23.3);KMT2A rearranged acute myeloid leukemia and acute lymphoblastic leukemia

Researchers

Presenter

  • Alison R. Walker

Principal Investigators

  • John C. Byrd

  • William Blum

  • Tara Lin

  • Howland E. Crosswell

  • Danjie Zhang

  • Jie Gao

  • Arati V. Rao

  • Mark D. Minden

  • Wendy Stock

Medical Centers

  • The Ohio State Univerisity, Columbus, OH

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • University of Kansas Medical Center, Kansas City, MO

  • Bon Secours St. Francis Health System, Greenville, SC

  • Gilead Sciences, Inc., Foster City, CA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • United States

  • Canada

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Histone-lysine N-methyltransferase 2A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Entospletinib

  • Daunorubicin

  • Vincristine

  • Cytarabine liposomal

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved